Articles written by STAT - Benzinga

STAT+: A scrap of data on Amgen's obesity drug candidate wipes out $12 billion in market value

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, spotted by an analyst at Cantor Fitzgerald, focused on

STAT+: Johnson & Johnson sues Biden administration over payment terms for 340B hospitals

Johnson & Johnson has sued a U.S. government agency over a closely watched dispute focusing on payment methods for some hospitals that participate in a federal drug discount program. In its lawsuit, the company

STAT+: DOJ sues to block UnitedHealth takeover of home health giant Amedisys

The Department of Justice on Tuesday sued to prevent UnitedHealth Group from buying Amedisys, one of the largest home health and hospice chains in the country. The DOJ’s lawsuit, which is joined by the

DOJ sues to block UnitedHealth takeover of home health giant Amedisys

The Department of Justice on Tuesday sued to prevent UnitedHealth Group from buying Amedisys, one of the largest home health and hospice chains in the country. The DOJ’s lawsuit, which is joined by the

The problem with Narcotics Anonymous & the Salvation Army

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning! A few of my wonderful colleagues are hosting a LinkedIn Live conversation today

STAT+: RNA startup Orna Therapeutics cuts more jobs

Biotech startup Orna Therapeutics has cut more jobs in its second round of layoffs in the last year, STAT has learned. Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic,

FDA commissioner suggests RFK Jr. and Trump might compromise an agency 'at peak performance'

WASHINGTON — Food and Drug Administration Commissioner Robert Califf said he’s unsure about the future of the agency under the incoming Trump administration and “disappointed” about the

STAT+: FDA commissioner suggests RFK Jr. and Trump might compromise an agency 'at peak performance'

WASHINGTON — Food and Drug Administration Commissioner Robert Califf said he’s unsure about the future of the agency under the incoming Trump administration and “disappointed” about the

STD epidemic slows as new syphilis and gonorrhea cases fall in U.S.

The U.S. syphilis epidemic slowed dramatically last year, gonorrhea cases fell and chlamydia cases remained below prepandemic levels, according to federal data released Tuesday. The numbers represented some good news

STAT+: Pharmalittle: We're reading about 23andMe retrenching, AstraZeneca reworking cancer drug plans, and more

Top of the morning to you. And a fine one it is. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search of creatures to

When even an 'over the wall' PIPE can't help

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. My colleagues

STAT+: Despite setback, AbbVie's big bet on neuroscience has yet to play out

For AbbVie, the good news this week is that the failure of a high-profile schizophrenia drug in two key trials hardly marks its last opportunity to make strides in neuroscience. The bad news is that the effort might not

STAT+: Fueled by a 'fall off your chair' discovery and $101 million, Trace launches to take on ALS

A surprise finding by two independent research teams and a venture capital mega-round have birthed a biotech looking to treat amyotrophic lateral sclerosis with a new strategy. Trace Neurosciences launched on Tuesday

The recovery community says it offers refuge from opioid addiction. But it's still hostile to lifesaving addiction medications

The last time Mark Palinski went to a Narcotics Anonymous meeting, he was asked to leave and never come back. He stills remembers the argument: All he had done was advocate for the use of the “gold

Opinion: How ADHD wired me for scientific discovery

Imagine a mind that’s constantly buzzing, leaping from one thought to the next, struggling to filter out the noise of a world that feels perpetually turned up to 11. That’s the experience of living with

STAT+: OpenAI isn't built for health care. So why is its tech already in hospitals, pharma, and cancer care?

The company behind ChatGPT didn’t set out to tackle health care. But despite ongoing concerns about its technology’s tendency to hallucinate, OpenAI is already inking deals with health care customers

STAT+: How Pfizer used wearables to tap into the promise of an experimental drug

Pfizer’s promising research on a treatment for a dangerous cancer-related condition is also helping prove out the value of wearables in clinical trials. In September, the pharma giant reported results showing

Opinion: Invest in 'triple rapid' tests to fight mpox, H5N1 bird flu, and beyond

This summer, the World Health Organization (WHO) declared the rapid spread of mpox in Africa a public health emergency of international concern. The WHO has reported over 46,000 suspected cases and 1,000 deaths

STAT+: AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of lung cancer, a step that will delay the drug’s arrival on the market and that

STAT+: The end of 23andMe's drug discovery dream

23andMe, the genetics startup that has repeatedly captured the public imagination and then faced nearly fatal business challenges, announced Monday that it would halt its efforts to develop new medicines and lay off 40%